ModerateSelective irreversible monoamine oxidase B inhibitor×Allylamine antifungal (systemic and topical)
Updated · Methodology
Mechanism
Terbinafine inhibits CYP2D6 and can turn an extensive CYP2D6 metaboliser into a poor metaboliser (terbinafine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and terbinafine label, US Food and Drug Administration, FDA). The US terbinafine label lists monoamine oxidase type B (MAO-B) inhibitors among the drug classes that CYP2D6 predominantly metabolises. The Spanish SmPC words this more cautiously and refers to 'certain products' in these classes that CYP2D6 mainly metabolises (terbinafine SmPC, AEMPS). According to the rasagiline documents, another enzyme, CYP1A2, mainly metabolises rasagiline, and they do not mention CYP2D6 (rasagiline SmPC, European Medicines Agency, EMA, and Azilect label, FDA). The documents contain no study of this pair, so it is not known how much rasagiline levels might change.
Symptoms
The documents describe no symptoms of this combination. Rasagiline itself can cause daytime sleepiness and sudden sleep episodes, especially with other dopaminergic drugs. Together with levodopa, it can lower blood pressure and worsen dyskinesia (rasagiline SmPC, European Medicines Agency, EMA). Hypomania, hypertensive crisis and serotonin syndrome have been reported after rasagiline overdose (rasagiline SmPC, EMA).
Management
No document contraindicates or prohibits this combination (rasagiline SmPC, European Medicines Agency, EMA, and Azilect label, US Food and Drug Administration, FDA; terbinafine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and terbinafine label, FDA). Under the US terbinafine label, combined use with monoamine oxidase type B (MAO-B) inhibitors needs careful monitoring, and the dose of the MAO-B inhibitor may need to be reduced (terbinafine label, FDA). The Spanish terbinafine SmPC asks for close monitoring of people who take drugs that CYP2D6 mainly metabolises, especially drugs with a narrow therapeutic margin (terbinafine SmPC, AEMPS). The documents do not say what exactly to monitor. The rasagiline SmPC warns about daytime sleepiness and sudden sleep episodes and advises caution when driving. It also warns about low blood pressure with levodopa and about worsening dyskinesia, which a lower levodopa dose may improve (rasagiline SmPC, EMA). The effect of terbinafine on CYP2D6 persists after terbinafine is stopped. In a study with desipramine, the effect was still present 4 weeks after the last dose (terbinafine label, FDA). Terbinafine can damage the liver, so check liver function before treatment and after 4–6 weeks (terbinafine SmPC, AEMPS). If a person taking rasagiline progresses from mild to moderate hepatic impairment, stop rasagiline (rasagiline SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.5 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Terbinafina, Terbinafina Normon 250 mg comprimidos (nº registro 68185), sección 4.4 (2026)– AEMPS, CIMA, nº registro 68185 (Terbinafina Normon 250 mg comprimidos EFG, Laboratorios Normon), revisión 10/2026, secciones 4.4 y 4.5
- FDA: Terbinafine tablets, Cipla (terbinafine) prescribing information (2025)– FDA, DailyMed setid 18b16aad-1877-4b07-b532-f0ef4843af91 (Cipla USA), versión 6, efectiva 09/2025, secciones 7 y 12.3